Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis
Key facts
- Who runs it
- St. Petersburg State Pavlov Medical University
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 20 people enrolled
- Started
- 1 Jun 2019
- Ended
- 29 Nov 2023
- Type of study
- Interventional
- Treatments tested
- allogeneic fecal microbiota
- Record updated
- 6 December 2023
- Why it stopped
- the bio-samples are corrupted for technical reasons
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Diagnosis: Multiple sclerosis (Relapsing-Remitting, Secondary-Progressive, Primary-Progressive)
- AutoHSCT
- Signed informed consent
- No second tumors
- No severe concurrent illness
- 1.0-6.5 points by EDSS
- Disease duration less than 20 years
- Disease progression on 1 and/or 2 line therapy (1 point EDSS 1.0-6.0 and 0,5 point EDSS 6.0-6.5)
Who cannot take part
- Uncontrolled bacterial or fungal infection at the time of enrollment
- Somatic or psychiatric disorder making the patient unable to sign informed consent
- Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%
- Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits
- Creatinine clearance < 60 mL/min
- Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted
- Respiratory distress >grade I
- Requirement for vasopressor support at the time of enrollment
- Karnofsky index <30%
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota. Therefore, transplantation of a normal fecal microbiota (FMT) can improve the outcome of autologous hematopoietic stem cell transplantation (autoHSCT) by increasing the disease-free period and disease progression suspension for at least 5 years after transplantation, which meets the NEDA (No Evidence of Disease Activity) criteria, satisfying the current trends of clinical neurology.
The group in the trial
- AutoHSCT + FMTTreatment being tested
AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
Treatment: allogeneic fecal microbiota
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Allogeneic Fecal Microbiota Transplantation as a Consolidation Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis
- Record updated
- 6 December 2023